The rate of dropout in studies of oral semaglutide has been significant, approximately 25% in recent trials, reflecting tolerability concerns, mainly due to nausea (source)
Several clinical trials have not shown a reduction of IAH by using CGM despite a reduced incidence of Level 3 hypoglycaemia [101, 112, 124, 126,127,128]
If you think this treatment may be right for you, you can read more about tirzepatide for weight management
S.et al
With growing popularity comes important news and updates that patients need to know
My concern is the habitual, long-term use and overutilization of prescription medication based on a lack of health literacy of the patient and, quite frankly, many of the doctors who prescribe medication